- Home
- ABEO vs PROK Comparison
ABEO vs PROK Comparison
Compare ABEO & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABEO
- PROK
- Stock Information
- Founded
- ABEO N/A
- PROK 2015
- Country
- ABEO United States
- PROK United States
- Employees
- ABEO N/A
- PROK N/A
- Industry
- ABEO Biotechnology: Pharmaceutical Preparations
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABEO Health Care
- PROK Health Care
- Exchange
- ABEO Nasdaq
- PROK Nasdaq
- Market Cap
- ABEO 247.8M
- PROK 237.4M
- IPO Year
- ABEO 1980
- PROK N/A
- Fundamental
- Price
- ABEO $5.70
- PROK $1.53
- Analyst Decision
- ABEO Strong Buy
- PROK Buy
- Analyst Count
- ABEO 3
- PROK 5
- Target Price
- ABEO $18.00
- PROK $4.50
- AVG Volume (30 Days)
- ABEO 229.2K
- PROK 500.4K
- Earning Date
- ABEO 11-14-2024
- PROK 11-12-2024
- Dividend Yield
- ABEO N/A
- PROK N/A
- EPS Growth
- ABEO N/A
- PROK N/A
- EPS
- ABEO N/A
- PROK N/A
- Revenue
- ABEO N/A
- PROK N/A
- Revenue This Year
- ABEO N/A
- PROK N/A
- Revenue Next Year
- ABEO $18,714.71
- PROK N/A
- P/E Ratio
- ABEO N/A
- PROK N/A
- Revenue Growth
- ABEO 147.52
- PROK N/A
- 52 Week Low
- ABEO $3.05
- PROK $1.18
- 52 Week High
- ABEO $9.01
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- ABEO 34.30
- PROK 36.04
- Support Level
- ABEO $5.45
- PROK $1.70
- Resistance Level
- ABEO $6.04
- PROK $2.03
- Average True Range (ATR)
- ABEO 0.19
- PROK 0.19
- MACD
- ABEO -0.04
- PROK -0.06
- Stochastic Oscillator
- ABEO 19.47
- PROK 8.33
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.